How Will the Market React to CTI BioPharma Corp (CTIC) Stock Getting a Bullish Rating

Thursday, June 22, 2023 02:08 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to CTI BioPharma Corp (CTIC) Stock Getting a Bullish Rating

The market has been high on CTI BioPharma Corp (CTIC) stock recently. CTIC gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

CTI BioPharma Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTIC!

See Full CTIC Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CTIC Stock Today?

CTI BioPharma Corp (CTIC) stock is down -0.11% while the S&P 500 is higher by 0.19% as of 2:08 PM on Thursday, Jun 22. CTIC has fallen -$0.01 from the previous closing price of $9.10 on volume of 420,635 shares. Over the past year the S&P 500 has risen 16.18% while CTIC is higher by 55.65%. CTIC lost -$0.58 per share in the over the last 12 months. To screen for more stocks like CTI BioPharma Corp click here.

More About CTI BioPharma Corp

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis. Click Here to get the full Stock Report for CTI BioPharma Corp stock.